Joke Muyldermans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Joke Muyldermans has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Eline Tommelein
Department of Pharmaceutical and Pharmacological Sciences, Experimental Pharmacology, Vrije Universiteit Brussel, Belgium
2 shared publications - Isabelle Desombere
Department of Infectious Diseases in Humans, Sciensano, Brussels, Belgium
1 shared publication Joeri Aerts
Neuro-Aging & Viro-Immunotherapy (NAVI), Department of Pharmaceutical Sciences (FARM), Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Jette, Belgium
1 shared publication- Kathrin Gerling
Karlsruhe Institute of Technology
1 shared publication Kirsten Maertens
Centre for the Evaluation of Vaccination, Vaccine & Infectious Diseases Institute, University of Antwerp, Wilrijk, Belgium
1 shared publication- Kymeng Tang
KU Leuven, Belgium
1 shared publication
Latest Publications
- 27 March 2026
- Published by SAGE Publications in Journal of Human Lactation
The COVALAC Study: The Impact of COVID-19 Vaccination During Lactation on SARS-CoV-2-Specific Antibodies in Human Milk—A Prospective Cohort Study
Background: The COVID-19-pandemic prompted global vaccination campaigns, raising important questions about vaccine-induced immune responses in lactating women and the transfer of SARS-CoV-2-specific antibodies through human milk. This study investigated the presence of SARS-CoV-2-specific IgA and IgG antibodies in breastmilk for up to 6 months following COVID-19 vaccination and booster doses with either mRNA or adenoviral vector (AVV) vaccines. Method: The COVALAC-study was a prospective cohort study conducted in Belgium. Women were recruited between February and March 2021, followed for 180 days post-vaccination and 28 days post-booster. Breastmilk samples were collected at multiple timepoints and analyzed for IgA and IgG antibodies. Participants received either mRNA (BNT162b2, mRNA-127) or AVV (ChAdOx1 nCoV-19) vaccines. Antibody concentrations were measured using an in-house immunoassay, and analyses compared responses between vaccine types. Results: Of the 115 participants, 40% received BNT162b2, 4.3% mRNA-1273, and 55.7% ChAdOx1-S as their primary vaccination. Of these, 31 participants received an mRNA booster (11 homologous, 20 heterologous boosters). IgA and IgG antibody levels were monitored pre- and post-vaccination, showing a stronger antibody response after mRNA vaccination compared to AVV, after roughly 14 days (IgA receptor binding domain [RBD] 1.13 BAU/mil; 0.61–1.67; IgG RBD 2.56 BAU/mil; 0.76–4.71, up to 1 month, for most antibodies. Both homologous and heterologous boosters further increased antibody titers (IgA RBD 0,85 BAU/ml; 1.09–1.72). Conclusion: COVID-19 vaccination during lactating induces SARS-CoV-2 specific IgA and IgG antibodies in human milk. Antibody levels were higher following mRNA vaccination compared to AVV vaccination, with booster doses enhancing these levels further.
- 27 March 2026
- Published by SAGE Publications in Journal of Human Lactation
The COVALAC Study: The Impact of COVID-19 Vaccination During Lactation on SARS-CoV-2-Specific Antibodies in Human Milk—A Prospective Cohort Study
Background: The COVID-19-pandemic prompted global vaccination campaigns, raising important questions about vaccine-induced immune responses in lactating women and the transfer of SARS-CoV-2-specific antibodies through human milk. This study investigated the presence of SARS-CoV-2-specific IgA and IgG antibodies in breastmilk for up to 6 months following COVID-19 vaccination and booster doses with either mRNA or adenoviral vector (AVV) vaccines. Method: The COVALAC-study was a prospective cohort study conducted in Belgium. Women were recruited between February and March 2021, followed for 180 days post-vaccination and 28 days post-booster. Breastmilk samples were collected at multiple timepoints and analyzed for IgA and IgG antibodies. Participants received either mRNA (BNT162b2, mRNA-127) or AVV (ChAdOx1 nCoV-19) vaccines. Antibody concentrations were measured using an in-house immunoassay, and analyses compared responses between vaccine types. Results: Of the 115 participants, 40% received BNT162b2, 4.3% mRNA-1273, and 55.7% ChAdOx1-S as their primary vaccination. Of these, 31 participants received an mRNA booster (11 homologous, 20 heterologous boosters). IgA and IgG antibody levels were monitored pre- and post-vaccination, showing a stronger antibody response after mRNA vaccination compared to AVV, after roughly 14 days (IgA receptor binding domain [RBD] 1.13 BAU/mil; 0.61–1.67; IgG RBD 2.56 BAU/mil; 0.76–4.71, up to 1 month, for most antibodies. Both homologous and heterologous boosters further increased antibody titers (IgA RBD 0,85 BAU/ml; 1.09–1.72). Conclusion: COVID-19 vaccination during lactating induces SARS-CoV-2 specific IgA and IgG antibodies in human milk. Antibody levels were higher following mRNA vaccination compared to AVV vaccination, with booster doses enhancing these levels further.
- 19 February 2026
- Published by SAGE Publications in Journal of Human Lactation
- Vol. 42 (1) , 105-115
Peri-Surgical Support: Experiences of Breastfeeding Women
Background: Breastfeeding continuation can be challenging for patients undergoing surgical procedures. Guidelines regarding peri-surgical measures and medication use are available, but it is not clear to what extent these are applied in clinical practice and how the care is experienced by breastfeeding mothers. Research Aim: To describe patient perspectives on perioperative support for breastfeeding mothers undergoing surgical procedures. Methods: An online, cross-sectional study was conducted among adult Belgian women who received analgesics or anesthetics during a surgical procedure while breastfeeding. The pre-tested survey assessed beliefs about breastfeeding and its health benefits, perioperative practices used and experienced, medication use, and advice related to breastfeeding and human milk. Results: From September 2021 through April 2022, 193 participants completed the questionnaire. In all, 45 participants (23.3%) reported that no healthcare provider asked about their breastfeeding status prior to their procedure, and 43 (22.3%) reported no discussion on medication use and safety during breastfeeding. Guidance on breastfeeding management varied widely, with conflicting advice: 47 (24.4%) were advised to breastfeed immediately after the procedure, while 84 (43.5%) ultimately did. In contrast, 11 (5.7%) were advised to express and discard their milk once, 37 (19.2%) for 12 hours, and 31 (16.1%) for 24 hours after the procedure, while 10 (5.2%), 28 (14.5%), and 21 (10.9%) ultimately did, respectively. Many sought information beyond their healthcare team, for example, in online forums ( n = 77; 39.9%) and websites ( n = 50; 25.9%). Conclusions: While awareness of breastfeeding benefits is generally good amongst breastfeeding mothers, women’s experiences around breastfeeding support during surgical procedures vary, often not reflecting the most recent evidence-based standards. Better education of healthcare professionals, more comprehensive surgical protocols, or greater awareness of existing guidelines could help to meet the need for breastfeeding support during surgery.
- 19 February 2026
- Published by SAGE Publications in Journal of Human Lactation
- Vol. 42 (1) , 105-115
Peri-Surgical Support: Experiences of Breastfeeding Women
Background: Breastfeeding continuation can be challenging for patients undergoing surgical procedures. Guidelines regarding peri-surgical measures and medication use are available, but it is not clear to what extent these are applied in clinical practice and how the care is experienced by breastfeeding mothers. Research Aim: To describe patient perspectives on perioperative support for breastfeeding mothers undergoing surgical procedures. Methods: An online, cross-sectional study was conducted among adult Belgian women who received analgesics or anesthetics during a surgical procedure while breastfeeding. The pre-tested survey assessed beliefs about breastfeeding and its health benefits, perioperative practices used and experienced, medication use, and advice related to breastfeeding and human milk. Results: From September 2021 through April 2022, 193 participants completed the questionnaire. In all, 45 participants (23.3%) reported that no healthcare provider asked about their breastfeeding status prior to their procedure, and 43 (22.3%) reported no discussion on medication use and safety during breastfeeding. Guidance on breastfeeding management varied widely, with conflicting advice: 47 (24.4%) were advised to breastfeed immediately after the procedure, while 84 (43.5%) ultimately did. In contrast, 11 (5.7%) were advised to express and discard their milk once, 37 (19.2%) for 12 hours, and 31 (16.1%) for 24 hours after the procedure, while 10 (5.2%), 28 (14.5%), and 21 (10.9%) ultimately did, respectively. Many sought information beyond their healthcare team, for example, in online forums ( n = 77; 39.9%) and websites ( n = 50; 25.9%). Conclusions: While awareness of breastfeeding benefits is generally good amongst breastfeeding mothers, women’s experiences around breastfeeding support during surgical procedures vary, often not reflecting the most recent evidence-based standards. Better education of healthcare professionals, more comprehensive surgical protocols, or greater awareness of existing guidelines could help to meet the need for breastfeeding support during surgery.
- Open Access
- 3 September 2023
- Published by Association for Computing Machinery (ACM)
- p. 186-196
3, 2, 1 Start with Breastfeeding: Supporting Partner Involvement in Breastfeeding Education Through a Gamified Mobile App
- 3 September 2023
- Published by Association for Computing Machinery (ACM)
- p. 186-196
Open Access3, 2, 1 Start with Breastfeeding: Supporting Partner Involvement in Breastfeeding Education Through a Gamified Mobile App